首页> 外文期刊>Nutrition Metabolism >Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial
【24h】

Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial

机译:对2型糖尿病的超重和肥胖患者的代谢和临床反应对2型糖尿病患者的补充:双盲,随机安慰剂对照临床试验

获取原文
           

摘要

Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM. Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo (n?=?30) and BP (n?=?30). The supplementation was considered one 1000?mg capsule 2 times /day BP by meals (lunch and dinner) for 8?weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum nesfatin-1 level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed. In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (P 0.05). BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results.
机译:糖尿病是全世界最常见的代谢紊乱。我们的旨在确定对T2DM的超重和肥胖患者的补充兔子的代谢和临床反应。参与者招募在Zahedan Bu-Ali医院的糖尿病诊所进行。由于资格标准,60名参与者将60个参与者随机分为两组,即安慰剂(N?=?30)和BP(n?=?30)。补充被认为是1000粒胶囊2次/天BP(午餐和晚餐)8?周。身体活动水平,膳食摄入量,人体测量测量[重量,高度和腰围],血糖指数[禁食血糖(FBG)和胰岛素(FBI)],血脂[甘油三酯(TG),总胆固醇(TC),高 - 测定密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)]和血清Nesfatin-1水平。稳态模型评估 - 胰岛素抵抗(HOMA-IR),计算定量胰岛素敏感性检查指数(Quicki)和体重指数(BMI)。与安慰剂相比,BP显着降低了FBG,HOMA-IR和BMI(P 0.05)。 BP补充改善超重和肥胖的T2DM患者中的血清葡萄糖指数和BMI。需要进一步试验来确认结果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号